A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration Clinical Trial

Official title:
A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD

Status Completed

Clinical Trial Summary

To evaluate the efficacy and safety of KPS-0373 in patients with SCD.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01004016
Study type	Interventional
Source	Kissei Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase	Phase 2

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01970098` - A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT02889302` - An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT04107740` - C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration	Phase 4
Completed	`NCT01970124` - A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT01970137` - A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT01970111` - An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT00863538` - Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 2